Research programme: anti-infective therapeutics - Appili

Drug Profile

Research programme: anti-infective therapeutics - Appili

Alternative Names: ATI-1501; ATI-1503

Latest Information Update: 27 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Appili Therapeutics
  • Class Anti-infectives; Antibacterials; Small molecules
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Clostridium infections
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Anaerobic infections; Gram-negative infections

Most Recent Events

  • 12 Apr 2016 Preclinical trials in Anaerobic infections in USA (PO)
  • 12 Apr 2016 Preclinical trials in Gram-negative infections in USA (unspecified route)
  • 12 Apr 2016 ATI 1501 receives Orphan Drug status for Clostridium infections in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top